Delivery Order SPE2DB24D2010-SPE2DB25FABFZ
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $12,445.76 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The...
- The Defense Logistics Agency awarded a delivery order valued at $9,048.55 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) on June 18, 2025, with completion scheduled for June 20, 2025. This competitively awarded, firm fixed-price delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The product will be...
- AmerisourceBergen Drug Corp has been awarded a delivery order valued at $4,797.24 by the Defense Logistics Agency (DLA) for the supply of OTEZLA 30 mg tablets (60-count units). The contract carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded through open procurement. The award was executed on May 27, 2025, with an ultimate completion date of May 28, 2025, and the products will be delivered to AmerisourceBergen's corporate office location in...
- The Defense Logistics Agency awarded a delivery order valued at $5,018.16 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count units). This firm fixed-price contract, awarded on July 18, 2025, represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The award was made through open competition with no set-aside designation, and performance...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order on September 9, 2025, by the Defense Logistics Agency (DLA) for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $78,825.44. The contract is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025, and carries no set-aside designation, indicating it was awarded through open competition. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Otezla 30 mg tablets in a quantity of 60s at a firm fixed price of $2,802.78, with completion scheduled for September 9, 2025. This competitively awarded, non-set-aside contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, has been awarded a delivery order by the Defense Logistics Agency for the supply of Otezla 30 mg tablets (60-count unit) with a ceiling value of $7,874.42. This contract represents a firm fixed-price delivery order with an ultimate completion date of September 3, 2025, and carries no set-aside designation, indicating it was competitively awarded. The award is structured as a child...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency on August 13, 2025, for the supply of Otezla 30 mg tablets (60-count units) with a ceiling value of $60,644.38. The contract carries a firm fixed price structure with an ultimate completion date of August 14, 2025, and was competitively awarded with no set-aside designation. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Otezla 30 mg tablets (60-count) under a firm fixed price contract valued at $6,381.96, with an ultimate completion date of August 15, 2025. This non-set-aside competitive award represents a child contract action under AmerisourceBergen's larger indefinite delivery vehicle with DLA. AmerisourceBergen, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $3,785.70 to AmerisourceBergen Drug Corp for the supply of Otezla 30 mg tablets (60-count) under a firm fixed price contract. The award was issued on July 28, 2025, with an ultimate completion date of July 29, 2025. This delivery order represents a non-competitive purchase executed under an existing contract vehicle and will be performed at the vendor's location in Conshohocken, Pennsylvania. This delivery order is a child...
- SPE2DB24D2010Indefinite Delivery Contract
- SPE2DB24D2010-SPE2DB25FABFZDelivery Order
AmerisourceBergen Drug Corp was awarded a delivery order valued at $35,330.15 by the Defense Logistics Agency (DLA) on September 17, 2025, for the supply of Otezla 30 mg tablets (60-count units). This firm fixed-price, competitively awarded contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The contract carries no set-aside designation, and the place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of September 18, 2025. As a major pharmaceutical distributor and critical federal healthcare vendor, AmerisourceBergen Drug Corp supplies a comprehensive range of pharmaceutical products and medical devices to support military and veteran healthcare systems. The company's extensive portfolio of delivery orders through the DLA demonstrates its capability to fulfill diverse medical procurement requirements, including specialty medications, vaccines, and medical supplies across multiple therapeutic domains. This particular award for Otezla—a prescription medication used to treat plaque psoriasis, psoriatic arthritis, and Behçet's disease—reflects the company's ongoing role in supporting the Defense Health Agency and other federal healthcare systems through the flexible and comprehensive pharmaceutical supply vehicle.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $35.3k | 9/17/25 |